Corvas International, Inc.

Other

Dart Neuroscience, (cayman) Ltd.

Ontogen Corporation

Novo Nordisk A/s

Envivo Pharmaceuticals, Inc.

Alla Chem, LLC

Selexagen Therapeutics, Inc.

William Charles Ripka

Ruth F Nutt

Joseph Edward Semple

Terence Kevin Brunck

Susan Yoshiko Tamura

Yu Ge

Robert J Ardecky

Odile Esther Levy

Thomas R Webb

Marguerita S Lim-Wilby

Stephen H Carpenter

Todd Kevin Jones

Henrik Sune Andersen

Ole Hvilsted Olsen

Sven Branner

Farid Bakir

Daniel Dale Holsworth

Frank Urban Axe

Lars Fogh Iversen

Luke Milburn Judge

Roy Teruyuki Uyeda

Jean-Michel Andre Vernier

Alan P Kaplan

Mi Chen

Mark E Wilson

Terence P Keenan

Matthew M Abelman

Romaine R Maiefski

Ignace Lasters

Michael I Weinhouse

Raymond Dagnino, Jr

John Eugene Reiner

Andrew Lindstrom

Don Wendell

Jonathan D Krakover

Niels Peter Hundahl M&oslash;ller

Patrick O'Connor

John May

David C Rowley

Marc De Maeyer

Anthony B Pinkerton

David J Matthews

Nikolay Filippovich Savchuk

Ilya Okun

Stephanie Hopkins

Pierre-Yves Bounaud

Alexander Khvat

Sergey Yevgenievich Tkachenko

Niels Peter Hundahl Møller

Christopher J Cummings

Borys Rogovoy

David A Lowe

The invention includes a compound of formula I: wherein R, Y, A, n, Rand Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impairment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.

Therapeutic piperazines

Described herein are compounds, pharmaceutical compositions and methods for the inhibition of Hedgehog signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human and veterinary disease and disorders.

Hedgehog inhibitors

Described herein are compounds, pharmaceutical compositions and methods for the inhibition of Hedgehog signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human and veterinary diseases and disorders.

Antagonist of smoothened

The present invention relates to a class of small molecule hydroxamic acid compounds capable of inhibiting histone deacetylases (HDACs). The present invention also relates to methods of preparation of hydroxamic acid HDAC inhibitor compounds of the invention, which are N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives, and their incorporation into pharmaceutical compositions and methods of administration. The present invention also relates to N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives, which may be prepared as a hydroxamic acid HDAC inhibitor compound library that can be utilized in screening methods known in the art.

Compounds for treatment of neurodegenerative diseases

The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&#x3b1;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases)

A multiple channel high throughput purification system for purifying a plurality of samples, preferably four or more samples from a chemical library. The high throughput purification uses chromatography, and more preferably, super critical fluid chromatography. Four parallel channels are provided in this system and coupled to a common analyzer and computer. The four channels direct the selected sample flow through a separator, such as an SFC column, a detector, such as a UV detector, to detect peaks within the sample flow, and a micro sample valve that splits a sampling of the flow to an analyzer, such as a mass spectrometer. The system also utilizes unique back pressure regulator assemblies and pressure relief assemblies to maintain a selected pressure within the purification channel. While the sample flow continues, the mass spectrometer simultaneously analyzes the sampling to determine if a target compound is within the sample portion.

Apparatus and method for multiple channel high throughput purification

The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B. CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

Modulators of protein tyrosine phosphatases (PTPases)

The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.

Aromatic heterocyclic derivatives as enzyme inhibitors

A multiple channel high throughput purification system for purifying a plurality of samples, preferably four or more samples from a chemical library. The high throughput purification uses chromatography, and more preferably, super critical fluid chromatography. Four parallel channels are provided in this system and coupled to a common analyzer and computer. The four channels direct the selected sample flow through a separator, such as an SFC column, a detector, such as a UV detector, to detect peaks within the sample flow, and a micro sample valve that splits a sampling of the flow to an analyzer, such as a mass spectrometer. The system also utilizes unique back pressure regulator assemblies and pressure relief assemblies to maintain a selected pressure within the purification channel. While the sample flow continues, the mass spectrometer simultaneously analyzes the sampling to determine if a target compound is within the sample portion. A fraction collection valve directs sample portions to one of two fraction collectors such as a microtiter plate. The purified target compounds are collected in one microtiter plate and the other non-desirable peaks are collected in a second microtiter plate in corresponding wells. In the supercritical fluid chromatography purification system, an expansion chamber is provided to condense the vaporous sample flow before the purified compounds are added to the particular well of the microtiter plate. A fraction collection assembly is used that automates the use of disposable expansion chambers for depositing the samples in the microtiter plates.

The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP&agr;, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

Modulators of protein tyrosine phosphatases (PTPASES)

3-amino-2-oxo-1-piperidnercetic derivatives as enzyme inhibitors

Aromatic hetherocyclic derivatives as enzyme inhibitors

The present invention discloses peptide aldehydes having a lactam group as part of the peptide backbone and having an original mimic group such as an amidinopiperidine or amidinophengyl tail. These compounds are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.

3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine

Growing community of inventors

San Diego, CA, United States of America

William Charles Ripka